Pemazyre 4.5 mg tablets, INCAGN02385, INCAGN02390, Retifanlimab (INCMGA00012)
INCMGA0012-204
Phase 2 small_molecule active
Quick answer
Pemazyre 4.5 mg tablets, INCAGN02385, INCAGN02390, Retifanlimab (INCMGA00012) for Endometrial cancer, Endometrial cancer is a Phase 2 program (small_molecule) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Incyte Biosciences Distribution B.V.
- Indication
- Endometrial cancer, Endometrial cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active